About 5'-nucleotidase domain-containing protein 1
5'-nucleotidase domain-containing protein 1 (NT5DC1) is a protein
from Homo sapiens identified by UniProt accession
Q5TFE4, 455 residues long.
MolForge cross-references it against 0 known binders and
77 disease associations.
Target properties
| Protein name | 5'-nucleotidase domain-containing protein 1 |
| UniProt accession | Q5TFE4 |
| Gene | NT5DC1 |
| Organism | Homo sapiens |
| Length | 455 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (77)
Diseases linked to this target (Open Targets).
- Metaphyseal chondrodysplasia, Schmid type · score 0.55
- refractive error · score 0.29
- hematocrit · score 0.28
- refractive error measurement · score 0.26
- alkaline phosphatase measurement · score 0.23
- Abnormality of refraction · score 0.23
- hemoglobin measurement · score 0.23
- Myopia · score 0.23
- age-related macular degeneration · score 0.19
- genetic disorder · score 0.19
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q5TFE4-F1 | alphafold | PREDICTED | 88.41 | — |
Amino-acid sequence (455 residues)
MAQHFSLAAC DVVGFDLDHT LCRYNLPESA PLIYNSFAQF LVKEKGYDKE LLNVTPEDWD FCCKGLALDL EDGNFLKLAN NGTVLRASHG TKMMTPEVLA EAYGKKEWKH FLSDTGMACR SGKYYFYDNY FDLPGALLCA RVVDYLTKLN NGQKTFDFWK DIVAAIQHNY KMSAFKENCG IYFPEIKRDP GRYLHSCPES VKKWLRQLKN AGKILLLITS SHSDYCRLLC EYILGNDFTD LFDIVITNAL KPGFFSHLPS QRPFRTLEND EEQEALPSLD KPGWYSQGNA VHLYELLKKM TGKPEPKVVY FGDSMHSDIF PARHYSNWET VLILEELRGD EGTRSQRPEE SEPLEKKGKY EGPKAKPLNT SSKKWGSFFI DSVLGLENTE DSLVYTWSCK RISTYSTIAI PSIEAIAELP LDYKFTRFSS SNSKTAGYYP NPPLVLSSDE TLISK
Explore 5'-nucleotidase domain-containing protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets